Your browser doesn't support javascript.
loading
Risk-Stratified Screening for Colorectal Cancer Using Genetic and Environmental Risk Factors: A Cost-Effectiveness Analysis Based on Real-World Data.
van den Puttelaar, Rosita; Meester, Reinier G S; Peterse, Elisabeth F P; Zauber, Ann G; Zheng, Jiayin; Hayes, Richard B; Su, Yu-Ru; Lee, Jeffrey K; Thomas, Minta; Sakoda, Lori C; Li, Yi; Corley, Douglas A; Peters, Ulrike; Hsu, Li; Lansdorp-Vogelaar, Iris.
Affiliation
  • van den Puttelaar R; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: r.vandenputtelaar@erasmusmc.nl.
  • Meester RGS; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Peterse EFP; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Zauber AG; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Zheng J; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Hayes RB; Division of Epidemiology, Department of Population Health, New York University School of Medicine, New York, New York.
  • Su YR; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Biostatistics Unit, Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
  • Lee JK; Division of Research, Kaiser Permanente Northern California, Oakland, California; Department of Gastroenterology, Kaiser Permanente San Francisco, San Francisco, California.
  • Thomas M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Sakoda LC; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Research, Kaiser Permanente Northern California, Oakland, California.
  • Li Y; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Corley DA; Division of Research, Kaiser Permanente Northern California, Oakland, California; Department of Gastroenterology, Kaiser Permanente San Francisco, San Francisco, California.
  • Peters U; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Hsu L; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Lansdorp-Vogelaar I; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
Clin Gastroenterol Hepatol ; 21(13): 3415-3423.e29, 2023 12.
Article in En | MEDLINE | ID: mdl-36906080
ABSTRACT
BACKGROUND &

AIMS:

Previous studies on the cost-effectiveness of personalized colorectal cancer (CRC) screening were based on hypothetical performance of CRC risk prediction and did not consider the association with competing causes of death. In this study, we estimated the cost-effectiveness of risk-stratified screening using real-world data for CRC risk and competing causes of death.

METHODS:

Risk predictions for CRC and competing causes of death from a large community-based cohort were used to stratify individuals into risk groups. A microsimulation model was used to optimize colonoscopy screening for each risk group by varying the start age (40-60 years), end age (70-85 years), and screening interval (5-15 years). The outcomes included personalized screening ages and intervals and cost-effectiveness compared with uniform colonoscopy screening (ages 45-75, every 10 years). Key assumptions were varied in sensitivity analyses.

RESULTS:

Risk-stratified screening resulted in substantially different screening recommendations, ranging from a one-time colonoscopy at age 60 for low-risk individuals to a colonoscopy every 5 years from ages 40 to 85 for high-risk individuals. Nevertheless, on a population level, risk-stratified screening would increase net quality-adjusted life years gained (QALYG) by only 0.7% at equal costs to uniform screening or reduce average costs by 1.2% for equal QALYG. The benefit of risk-stratified screening improved when it was assumed to increase participation or costs less per genetic test.

CONCLUSIONS:

Personalized screening for CRC, accounting for competing causes of death risk, could result in highly tailored individual screening programs. However, average improvements across the population in QALYG and cost-effectiveness compared with uniform screening are small.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Colorectal Neoplasms / Cost-Effectiveness Analysis Type of study: Diagnostic_studies / Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Adult / Aged / Aged80 / Humans / Middle aged Language: En Journal: Clin Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Colorectal Neoplasms / Cost-Effectiveness Analysis Type of study: Diagnostic_studies / Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Adult / Aged / Aged80 / Humans / Middle aged Language: En Journal: Clin Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2023 Type: Article